source
- Experts favor quadruplet regimens for newly diagnosed multiple myeloma, but transplant role remains debatedAt a recent multiple myeloma meeting, Dr. Ajai Chari of UCSF reviewed current frontline treatment strategies for newly diagnosed patients. He said that data from several phase-3 trials have shifte…
- FDA accepts supplemental NDA for taletrectinib targeting ROS1‑positive lung cancerThe U.S. Food and Drug Administration has accepted a supplemental New Drug Application for taletrectinib, a targeted therapy aimed at patients with ROS1‑positive non‑small cell lung cancer. The fi…